Search company, investor...

Cerimon Pharmaceuticals

Founded Year



Unattributed VC | Dead

Total Raised


Last Raised


About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to bringing innovative therapeutics to patients with substantial, unmet medical needs. The Company is engaged in the development and commercialization of therapeutics in the areas of autoimmune diseases, inflammation and pain. Cerimon was founded in November 2004 by Paul Sekhri, together with Ansbert Gadicke and Luke Evnin of MPM Capital, as a start-up biopharmaceutical company focused on innovative partnering deals with the pharmaceutical industry. Cerimon is headquartered in South San Francisco. For more information on Cerimon, please visit the Company's Website at .

Headquarters Location

701 Gateway Blvd. #100

South San Francisco, California, 94080,

United States


Missing: Cerimon Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cerimon Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Cerimon Pharmaceuticals News

Paul Sekhri to join vTv Therapeutics as CEO

Jul 27, 2022

Paul Sekhri has been appointed as president and CEO of clinical-stage biopharmaceutical company vTv Therapeutics (NASDAQ: VTVT ). Sekhri assumes the role on August 1, 2022, replacing interim CEO Rich Nelson, who will continue as EVP, Corporate Development and as a member of the board of directors. He hold nearly 30 years of healthcare experience, including serving as president and CEO of several healthcare companies such as eGenesis, Lycera, Cerimon Pharmaceuticals, as well as senior business development and strategy roles at Sanofi, Teva Pharmaceutical Industries, TPG Biotech, Cerimon, Ariad Pharmaceuticals and Novartis Pharma. The appointment comes at a time when vTv Therapeutics ( VTVT ) is set to launch Phase 3 pivotal studies for its most advanced product, TTP399. TTP399 has received Breakthrough Therapy designation by the U.S. FDA as an oral adjunctive therapy for the treatment of T1D. Recommended For You

Cerimon Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Cerimon Pharmaceuticals founded?

    Cerimon Pharmaceuticals was founded in 2004.

  • Where is Cerimon Pharmaceuticals's headquarters?

    Cerimon Pharmaceuticals's headquarters is located at 701 Gateway Blvd., South San Francisco.

  • What is Cerimon Pharmaceuticals's latest funding round?

    Cerimon Pharmaceuticals's latest funding round is Unattributed VC.

  • How much did Cerimon Pharmaceuticals raise?

    Cerimon Pharmaceuticals raised a total of $72.5M.

  • Who are the investors of Cerimon Pharmaceuticals?

    Investors of Cerimon Pharmaceuticals include MPM Capital, OrbiMed Advisors and Nomura Holdings.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.